natgillin/translations-raw huggingface dataset:
Patients in the Preotact treatment group had a 61% relative risk reduction of a new vertebral fracture at month 18 compared to the patients in the placebo group. 
U bolesnica liječenih Preotactom relativni rizik novih prijeloma kralježaka u 18 mjesecu terapije bio je smanjen za 61% u odnosu na skupinu koja je primala placebo.
Marketing Authorisation Holder NPS Pharma Holdings Limited Grand Canal House 1 Grand Canal Street Upper Dublin 4 
Nositelj odobrenja za stavljanje gotovog lijeka u promet NPS Pharma Holdings Limited Grand Canal House
A total of 238 postmenopausal women, were randomly assigned to one of the following treatment groups; Preotact (100 micrograms parathyroid hormone), alendronate (10 mg), or the combination of both, and followed for 12 months. 
Preotact (100 mikrograma paratireoidnog hormona), alendronat (10 mg), ili kombinacija oba lijeka, te praćeno tijekom 12 mjeseci.
For all subjects who received parathyroid hormone 100 micrograms blood uric acid increase was reported for 8 subjects (0.6%) and hyperuricemia was reported for 5 subjects (0.4%). 
Od svih ispitanica koje su primale 100 mikrograma paratireoidnog hormona, povećanje urične kiseline zabilježeno je kod 8 ispitanica (0,6%),
Preotact is used to treat osteoporosis in women past menopause with high risk of fractures. 
Preotact se koristi za liječenje osteoporoze kod žena u postmenopauzi koje imaju visoki rizik prijeloma kosti.
The pivotal study was an 18-month double-blind, placebo-controlled, phase III study (TOP) of the effect of Preotact on fracture incidence in women with postmenopausal osteoporosis. 
Pivotalno ispitivanje bilo je 18-mjesečno dvostruko slijepo, placebom kontrolirano ispitivanje faze III (TOP) o utjecaju
• Add a needle 
• Dodajte iglu
Hold on to the clear front end of the pre-filled pen and screw the needle all the way onto the clear front end of the pre-filled pen. 
Držeći napunjenu brizgalicu za prozirni prednji dio, zakretanjem navijte iglu sve do prozirnog prednjeg dijela napunjene brizgalice.
Reconstituted solution: Store in a refrigerator (2-8°C). 
Rekonstituirana otopina: Čuvati u hladnjaku (2-8oC).
Crimp cap (containing a rubber seal): Aluminium .The rubber seal is made of bromobutyl rubber. 
Navojni zatvarač (sadrži gumeni čep): Aluminij.
After reconstitution, each dose of 71.4 microlitre contains 100 micrograms parathyroid hormone. 
Nakon rekonstitucije, svaka doza od 71,4 mikrolitara sadrži 100 mikrograma paratireoidnog hormona.
• Calcium and vitamin D supplementation should be withdrawn 
• Nadomjeske kalcija i vitamina
Rats treated with near life-time daily injections had dose-dependent exaggerated bone formation and an increased incidence of bone tumours, including osteosarcoma, most probably due to an epigenetic mechanism. 
Štakorima koji su gotovo tijekom cijelog životnog vijeka primali dnevnu injekciju, vjerojatno zbog epigenetskog mehanizma, razvijali su o dozi ovisne koštane formacije i imali povećanu incidenciju koštanih tumora, uključujući osteosarkom.
Preotact should therefore not be used in patients with severe hepatic impairment (see section 4.3). 
Preotact se stoga ne smije koristiti u bolesnika s teškim oštećenjem jetre (vidjeti dio 4.3).
Powder and solvent for solution for injection. 
Prašak i otapalo za injekcijsku otopinu.
Your doctor may advise you to take supplementary calcium and vitamin D. Your doctor will tell you how much you should take each day. 
Liječnik će Vam reći koliku dozu morate uzimati svaki dan.
The container closure system is comprised of a dual-chamber cartridge, a center stopper, a crimp cap (containing a rubber seal) sealing the first chamber containing lyophilised powder and an end stopper sealing the second chamber containing the solvent for mixing. 
(sadrži gumeni čep) koji brtvi prvu komoru s liofiliziranim praškom i zadnjeg čepa koji brtvi drugu komoru s otapalom za miješanje.
• sodium chloride, 
• natrijev klorid,
• reddening of the skin (erythema) at injection site, 
• crvenilo kože (eritem) na mjestu uboda,
Preotact is supplied in a pre-filled pen containing a cartridge. 
Preotact dolazi u obliku napunjene brizgalice koja sadrži uložak.
• irritation of the skin at the injection site, 
• iritacija kože na mjestu uboda, • gubitak teka,
Preotact should therefore not be used in patients with severe renal impairment (see section 4.3). 
Preotact se stoga ne smije koristiti u bolesnika s teškim oštećenjem bubrega (vidjeti dio 4.3).
• decreased muscle strength, muscle cramps, dizziness, 
• gubitak mišićne snage, mišićni grčevi, omaglica,
Caution should be exercised in 
Potreban je oprez kod
Similarly, volumetric trabecular BMD at the total hip increased by 9, 6, and 2%, respectively, in the 3 groups. 
u cijelom kuku povećao se za 9%, 6%, odnosno, 2%, u te 3 grupe.
Serum calcium concentrations reach a maximum between 6 and 8 hours post dose and normally return to baseline by 20 to 24 hours after each administration of parathyroid hormone. 
Koncenracija serumskog kalcija dostiže maksimum između 6 i 8 sati nakon primjene i u pravilu se vraća na početnu vrijednost
The volume of distribution at steady-state following intravenous administration is approximately 5.4 l. Interindividual variability in the volume of distribution of parathyroid hormone is about 40%. 
Volumen distribucije u stanju dinamičke ravnoteže nakon intravenske primjene paratireoidnog hormona je otprilike 5,4 l.
PHARMACEUTICAL FORM AND CONTENTS Powder and solvent for solution for injection. 
OBLIK Prašak i otapalo za otopinu za injekciju.
Only mix one pen at the time. 
Izmiješajte lijek samo u jednoj brizgalici.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled pen contains 1.61 mg parathyroid hormone corresponding to 14 doses. 
KVALITATIVNI I KVANTITATIVNI SASTAV Svaka napunjena brizgalica sadrži 1,61 mg paratireoidnog hormona što odgovara 14 doza.
Once the cartridge is reconstituted it can be stored below 25°C for up to 7 days during the 28 day use time. 
Nakon pripreme uloška za primjenu, smije se čuvati na temperaturi do 25oC do 7 dana tijekom razdoblja uporabe od 28 dana.
Although gout, arthralgia and nephrolithiasis were reported as ADRs, the relationship to elevations in uric acid due to Preotact administration has not been fully established. 
Premda su giht, artralgija i nefrolitijaza prijavljeni kao nuspojave,
No studies have been conducted in patients with severe hepatic impairment. 
Ispitivanja na bolesnicima s teškim oštećenjem jetre nisu provedena.
Dysgeusia 
Disgeuzija Parozmija
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, any updated RMP should be submitted at the same time as the following Periodic Safety Update Report (PSUR). 
dopunjeni RMP mora se podnijeti istovremeno uz sljedeće Periodičko izvješće o neškodljivosti lijeka
Posology The recommended dose is 100 micrograms of parathyroid hormone administered once-daily 
Doziranje Preporučena doza je 100 mikrograma paratireoidnog hormona primijenjenog jednom dnevno.
After reconstitution, each dose of 71.4 microlitre contains 100 micrograms parathyroid hormone produced in Escherichia coli by recombinant DNA technology For a full list of excipients, see section 6.1. 
Nakon rekonstitucije, svaka doza od 71,4 mikrolitara sadrži 100 mikrograma paratireoidnog hormona proizvedenog u Escherichia coli rekombinantnom DNA tehnologijom.
Elevated serum calcium was observed during Preotact treatment. 
Tijekom liječenja Preotactom zabilježeno je povećanje kalcija u serumu.
Preotact is injected using a pre-filled pen. 
Preotact se uštrcava korištenjem napunjene brizgalice.
• citric acid monohydrate, 
• citratnu kiselinu hidrat,
• with severe hepatic impairment 
• s teškim oštećenjem bubrega • s teškim oštećenjem jetre
The first chamber contains 1.61 mg parathyroid hormone as powder and the second chamber contains 1.13 ml of solvent. 
Prva komora sadrži 1,61 mg paratireoidnog hormona u obliku praška, a druga 1,13 ml otapala.
Each cartridge inside the prefilled pen contains 1.61 mg parathyroid hormone and 1.13 ml solvent (14 doses). 
Svaki uložak unutar napunjene brizgalice sadrži 1,61 mg paratireoidnog hormona i 1,13 ml otapala (14 doza).
There is no data available in patients with severe hepatic impairment. 
Za bolesnike s teškim oštećenjem jetre nema dostupnih podataka.
• back pain, 
• bol u leđima,
Langebjerg 1, 4000 Roskilde 
Nycomed Danmark ApS Langebjerg 1, 4000 Roskilde Denmark
Parosmia 
PRIMJENU
• hydrochloric acid, 
• kloridnu kiselinu,
Effect on bone mineral density (BMD) 
Slično, volumetrijski trabekularni BMD
• increased level of alkaline phosphatase in the blood , 
• povećanje razine urične kiseline u krvi, • povećanje razine alkalne fosfataze u krvi,
• have a high level of calcium in your urine; 
• imate visoku razinu kalcija u mokraći;
Preotact 100 micrograms powder and solvent for solution for injection in a pre-filled pen Parathyroid hormone 
Preotact 100 mikrograma prašak i otapalo za otopinu za injekciju u napunjenim brizgalicama Paratireoidni hormon
Preotact is a powder and solvent for solution for injection in a pre-filled pen. 
Preotact je prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici.
THE PRE-FILLED PEN 
NAPUNJENA BRIZGALICA
Ask your doctor or pharmacist for advice before taking any medicine Do not use Preotact if you are pregnant or breast-feeding. 
Obratite se svom liječniku ili ljekarniku za savjet prije uzimanja bilo kojeg lijeka.
The medicinal product is supplied in a pre-filled pen containing a dual-chamber cartridge. 
Lijek dolazi u obliku napunjene brizgalice s uloškom sa dvije komore.
• constipation, diarrhoea, 
• zatvor, proljev,
Injection site irritation 
Iritacija na mjestu injekcije
Volumetric trabecular BMD at the lumbar spine increased by 38% over baseline at 18 months. 
Volumetrijski trabekularni BMD u lumbalnoj kralježnici povećao se tijekom
Each pre-filled pen contains 1.61 mg of parathyroid hormone as powder and 1.13 ml of solvent. 
Svaka napunjena brizgalica sadrži 1,61 mg paratireoidnog hormona u obliku praška i 1,13 ml otapala.
Each pre-filled pen contains 1.61 mg parathyroid hormone corresponding to 14 doses. 
Svaka napunjena brizgalica sadrži 1,61 mg paratiroidnog hormona što odgovara ukupno 14 doza.
• You can store the mixed pre-filled pen for up to 7 days outside the refrigerator (below 25°C) 
• Brizgalica se može čuvati najviše 7 dana izvan hladnjaka (na temperaturi do 25oC) tijekom razdoblja upotrebe od 28 dana
There is no data available in patients with severe renal impairment. 
Za bolesnike s teškim oštećenjem bubrega nema dostupnih podataka.
One year of therapy, showed the following results: the increases in lumbar spine BMD above baseline were similar in the Preotact and combination-therapy groups (6.3 and 6.1%, respectively), but were somewhat smaller in the alendronate group (4.6%). 
Jednogodišnje liječenje pokazalo je sljedeće rezultate: povećanje BMD iznad početnih vrijednosti u lumbalnoj kralježnici bilo je slično u grupi na Preotactu i grupi koja je primala kombiniranu terapiju
• with metabolic bone diseases other than primary osteoporosis (including hyperparathyroidism 
• s već postojećom hiperkaciemijom ili drugim poremećajima u metabolizmu kalcija i fosfora • s metaboličkim bolestima kostiju različitim od primarne osteoporoze (uključujući hiperparatireoidizam i Pagetovu bolest kostiju) • s neobjašnjivim porastom koštano-specifične alkalne fosfataze
There was a modest increase of about 20% in the mean baseline corrected exposure (AUC) to parathyroid hormone in a study conducted in 6 men and 6 women with moderate hepatic impairment as compared with a matched group of 12 subjects with normal hepatic function. 
U ispitivanju provedenom na 6 muškaraca i 6 žena sa blagim poremećajima funkcije jetre i usporedbom s grupom od 12 ispitanika s normalnom funkcijom jetre, primijećeno je malo povećanje od 20% u osnovnim vrijednostima izloženosti (AUC) paratiroidnom hormonu.
Management of elevated serum calcium 
Praćenje povećanja kalcija u serumu
Nervous system disorders Common 
Povećanje urične kiseline u serumu Poremećaji živčanog sustava Često
In the pivotal study, Preotact increased BMD in the lumbar spine after 18 months treatment by 6.5% compared with -0.3% for placebo (p<0.001). 
mjeseci liječenja u usporedbi sa -0,3% za placebo (p<0,001).
Injection site erythema 
Eritem na mjestu injekcije Umor
Overdose management 
Postupanje kod predoziranja
Keep the pre-filled pen in the outer carton in order to protect from light. 
Radi zaštite od svjetlosti, napunjenu brizgalicu čuvati u u kutiji.
Name and address of the manufacturer responsible for batch release Nycomed Danmark ApS 
Naziv i adresa proizvođača odgovornog za puštanje serije lijeka u promet
Blood calcium increased Uncommon 
Povećanje serumskog kalcija Manje često
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 1.61 mg parathyroid hormone and 1.13 ml solvent (14 doses) 
1,61 mg paratireoidnog hormona i 1,13 ml otapala (14 doza) OSTALO
Measuring of the calcium levels in the blood and/or urine Your doctor will check your response to the treatment at regular intervals. 
Vaš će liječnik redovito kontrolirati odgovor na terapiju.
Citric acid monohydrate Sodium chloride 
Prašak manitol citratna kiselina hidrat natrijev klorid kloridna kiselina, razrijeđena (za prilagodbu pH)
If you get any side effects talk to your doctor or pharmacist. 
Ako primjetite bilo koju nuspojavu obavijestite svog liječnika ili ljekarnika.
SUBSTANCE AND MANUFACTURING AUTHORISATION 
OBLIK I SADRŽAJ
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Preotact 100 micrograms powder and solvent for solution for injection Parathyroid hormone 
Uputa o lijeku: Informacija za korisnika Preotact 100 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici Paratireoidni hormon
What Preotact contains -The active substance is parathyroid hormone. 
Djelatna tvar je paratireoidni hormon.
STATEMENT OF ACTIVE SUBSTANCE(S) Each pre-filled pen contains 1.61 mg parathyroid hormone corresponding to 14 doses. 
KVALITATIVNI I KVANTITATIVNI SASTAV DJELATNIH TVARI Svaka napunjena brizgalica sadrži 1,61 mg paratireoidnog hormona što odgovara 14 doza.
NAME OF THE MEDICINAL PRODUCT Preotact 100 micrograms powder and solvent for solution for injection in a pre-filled pen. 
Preotact 100 mikrograma prašak i otapalo za otopinu za injekciju u napunjenoj brizgalici
• You can store the mixed pre-filled pen for up to 7 days at room temperature, between 2-25°C. 
• Napunjena brizgalica u kojoj je lijek izmiješan se smije čuvati do 7 dana na sobnoj temperaturi,
Renal and urinary disorders Very common 
Konstipacija Dispepsija Dijarea
General disorders and administration site conditions Common 
Opći poremećaji i reakcije na mjestu primjene
Headache 
Utjecaj
This overview was last updated in 09-2014. 
Ovaj sažetak je posljednji put ažuriran u 09. 2014.
Further information on Eliquis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Više informacija o lijeku Eliquis nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Thrombin is central to the process of blood clotting. 
Trombin ima ključnu ulogu u procesu zgrušavanja krvi.
This means that it blocks factor Xa, an enzyme that is involved in the production of thrombin. 
To znači da onemogućuje djelovanje faktora Xa, enzima koji sudjeluje u proizvodnji trombina.
What measures are being taken to ensure the safe and effective use of Eliquis? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Eliquis?
It is available as tablets (2.5 mg, 5 mg). 
Lijek Eliquis dostupan je u obliku tableta (2,5 mg, 5 mg).
For more information about using Eliquis, see the package leaflet or contact your doctor or pharmacist. 
Za više informacija o primjeni lijeka Eliquis, pogledajte uputu o lijeku ili se obratite liječniku ili ljekarniku.
Eliquis (apixaban) 
Eliquis (apiksaban)
Eliquis received a marketing authorisation valid throughout the EU on 18 May 2011. 
Lijek Eliquis dobio je odobrenje za stavljanje lijeka u promet koje je na snazi u Europskoj uniji od 18. svibnja 2011.
The most frequent side effects with Eliquis (seen in between 1 and 10 patients in 100) are anaemia (low red blood cell counts), haemorrhage (bleeding), haematoma (a collection of blood under the skin), contusion (bruising), nausea (feeling sick), low blood pressure (hypotension), epistaxis (nose bleeds), haematuria (blood in urine), low blood platelet counts (thrombocytopenia), blood tests showing alanine aminotransferase and gamma-glutamyltransferase increase and skin rash. 
Najčešće nuspojave koje nastaju uzimanjem lijeka Eliquis (zabilježene u 1 do 10 bolesnika na 100) jesu anemija (niski broj crvenih krvnih stanica), hemoragija (krvarenje), hematom (nakupljanje krvi ispod kože), kontuzija (modrice), mučnina (osjećaj slabosti), niski krvni tlak (hipotenzija), epistaksa (krvarenje iz nosa), hematurija (krv u mokraći), niski broj trombocita (trombocitopenija), krvne pretrage koje ukazuju na povišenje aspartat aminotransferaze, povišenje gama-glutamiltransferaze i kožni osip.
Similarly, patients with atrial fibrillation are at high risk of clots forming in the heart, which can reach the brain where they can cause a stroke. 
Slično tome, bolesnici s fibrilacijom atrija izloženi su visokom riziku od stvaranja ugrušaka u srcu, koji mogu doći do mozga i uzrokovati moždani udar.
Other information about Eliquis 
Ostale informacije o lijeku Eliquis
By blocking factor Xa, it reduces the levels of thrombin in the blood, which reduces the risk of blood clots forming in the arteries and veins. 
Blokiranjem faktora Xa smanjuje razine trombina u krvi, čime se smanjuje rizik od stvaranja krvnih ugrušaka u arterijama i venama.
Eliquis must not be used in patients who are actively bleeding, or who have liver disease which leads to problems with blood clotting and an increased risk of bleeding. 
Eliquis se ne smije primjenjivati u bolesnika s aktivnim krvarenjem ili koji imaju bolest jetre koja uzrokuje probleme sa zgrušavanjem krvi i povećani rizik od krvarenja.
The recommended dose is one 2.5 mg tablet taken by mouth twice a day, usually for over one month (32 to 38 days) after a hip replacement or for 10 to 14 days after a knee replacement. 
Preporučena doza je jedna tableta od 2,5 mg peroralno dvaput na dan, najčešće tijekom više od mjesec dana (32 do 38 dana) nakon ugradnje umjetnog kuka, odnosno tijekom 10 do 14 dana nakon ugradnje umjetnog koljena.
The company that markets Eliquis will provide educational material for healthcare professionals expected to prescribe Eliquis that addresses the risk of bleeding during treatment. 
Tvrtka koja stavlja lijek Eliquis u promet dostavit će edukativne materijale za zdravstvene radnike za koje se očekuje da će propisivati lijek Eliquis s informacijama o upravljanju rizikom od krvarenja tijekom liječenja.
Side effects reported with Eliquis are carefully evaluated and any necessary action taken to protect patients. 
Nuspojave prijavljene za lijek Eliquis pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
What is Eliquis and what is it used for? 
Što je Eliquis i za što se primjenjuje?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Eliquis have also been included in the summary of product characteristics and the package leaflet. 
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Eliquis nalaze se također u sažetku opisa svojstava lijeka i u uputi o lijeku.
It is used in patients who have one or more risk factors, such as having had a previous stroke, having high blood pressure, diabetes, heart failure or being 75 years old or over. 
Primjenjuje se u bolesnika s jednim ili više čimbenika rizika, kao što su prethodna epizoda moždanog udara, visoki krvni tlak, dijabetes, zatajenje srca ili starost iznad 75 godina.
The European Medicines Agency decided that Eliquis' benefits are greater than its risks and it can be authorised for use in the EU. 
Europska agencija za lijekove zaključila je da koristi od lijeka Eliquis nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
Patients undergoing hip or knee replacement surgery, who have had a recent trauma, or are confined to bed are at a high risk of blood clots forming in the veins, which can be dangerous and even fatal if they move to another part of the body such as the lungs. 
Bolesnici na kojima se izvodi zahvat ugradnje umjetnog kuka ili koljena, koji su nedavno doživjeli traumu ili moraju ležati, izloženi su visokom riziku od krvnih ugrušaka koji nastaju u venama, što može biti opasno, pa čak i smrtonosno ako prijeđu u neki drugi dio tijela, kao što su pluća.
As for all medicines, data on the use of Eliquis are continuously monitored. 
Kao i za sve lijekove, podatci o primjeni lijeka Eliquis kontinuirano se prate.
Some of these side effects are not seen with all the uses of Eliquis. 
Neke od tih nuspojava nisu uočene sa svim oblicima primjene lijeka Eliquis.
In patients undergoing a knee replacement, the corresponding numbers were 15% (147 out of 976) for Eliquis compared with 24% (243 out of 997) for enoxaparin. 
U bolesnika koji su prošli zahvat ugradnje umjetnog koljena odgovarajuće brojke iznosile su 15 % (147 od 976) za Eliquis u usporedbi s 24 % (243 od 997) za enoksaparin.
For patients who have had a hip or knee replacement, treatment with Eliquis should be started 12 to 24 hours after the operation. 
Bolesnici na kojima je izveden zahvat ugradnje umjetnog kuka ili koljena trebali bi započeti liječenje lijekom Eliquis 12 do 24 sata nakon zahvata.
2.3% of patients taking Eliquis (2.5 mg twice a day) experienced a clot or died, compared with 9.3% of patients taking placebo. 
2,3 % bolesnika koji su uzimali Eliquis (2,5 mg dvaput dnevno) doživjelo je ugrušak ili je umrlo, u usporedbi s 9,3 % bolesnika koji su uzimali placebo.
The yearly rates in the second study were 1.6% for patients taking Eliquis and 3.6% for patients taking aspirin. 
Godišnje stope u drugom ispitivanju iznosile su 1,6 % za bolesnike koji su uzimali Eliquis, odnosno 3,6 % za bolesnike koji su uzimali aspirin.
Eliquis was also effective at treating deep vein thrombosis and pulmonary embolism and preventing their reoccurrence in two main studies. 
Eliquis je također bio učinkovit u liječenju duboke venske tromboze i plućne embolije i sprječavanju njihova ponavljanja u dvama glavnim ispitivanjima.
An overview of Eliquis and why it is authorised in the EU 
Pregled informacija o lijeku Eliquis i zašto je odobren u EU-u
Eliquis can only be obtained with a prescription. 
Eliquis se izdaje samo na liječnički recept.
Why is Eliquis authorised in the EU? 
Zašto je lijek Eliquis odobren u EU-u?
For the treatment of deep vein thrombosis and pulmonary embolism, the recommended dose is 10 mg twice a day for the first week, followed by 5 mg twice a day for at least 3 months. 
Kod liječenja duboke venske tromboze i plućne embolije preporučena doza iznosi 10 mg dvaput dnevno tijekom prvog tjedna, nakon čega slijedi 5 mg dvaput dnevno najmanje 3 mjeseca.
The medicine must also not be used in patients with conditions putting them at risk of major bleeding, such as an ulcer in the gut, or in patients being treated with other anticoagulant medicines except in specific circumstances (see summary of product characteristics). 
Nadalje, lijek se ne smije primjenjivati kod bolesnika koji pate od stanja zbog kojih su pod rizikom od značajnog krvarenja, kao što je čir na crijevima, ili koji se liječe drugim antikoagulansima, osim u određenim okolnostima (vidjeti sažetak opisa svojstava lijeka).
Additionally, Eliquis is used to prevent stroke (caused by blood clots in the brain) and blood clots in other organs in adults with atrial fibrillation (irregular rapid contractions of the upper chambers of the heart). 
Dodatno, Eliquis se primjenjuje za sprječavanje moždanog udara (izazvanog krvnim ugrušcima u mozgu) i krvnih ugrušaka u drugim organima u odraslih bolesnika s fibrilacijom atrija (nepravilnim brzim kontrakcijama gornjih srčanih šupljina).